

---

# **A PHARMACEUTICAL CARE PLAN TO MINIMIZE THE INCIDENCE OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGY PATIENTS**

A Thesis

Submitted for fulfillment of Master Degree in Pharmaceutical Sciences  
(Clinical Pharmacy)

Submitted by:

**Sarah Nabil Sobhy Hanna**  
B.Sc of pharmaceutical Sciences (2008)  
Faculty of Pharmacy  
Ain Shams University

Supervised by:

**Prof. Dr. Osama Ahmed Badary**  
Professor and Head of Department of Clinical Pharmacy  
Faculty of Pharmacy  
Ain Shams University

**Prof. Dr. Sohair Sayed Esmaeel**  
Professor of Oncology  
Faculty of Medicine  
Ain Shams University

**Dr. Mahmoud Abbass El-Laithy**  
Lecturer of Oncology  
Faculty of Medicine  
Ain Shams University

**Faculty of Pharmacy  
Ain Shams University  
2012**

---

## **List of contents**

<b>Acknowledgement</b> .....	III
<b>List of abbreviations</b> .....	IV
<b>List of tables</b> .....	V
<b>List of figures</b> .....	VII
<b>Abstract</b> .....	VIII
<b>Chapter 1: Introduction</b> .....	1
1.1 Components and scope of clinical pharmacy practice.....	1
1.2 Role of clinical pharmacist in oncology unit .....	1
1.3 Review of the role of oncology clinical pharmacist in literature.....	3
1.4 Adverse drug reactions and drug-drug interactions .....	5
1.5 Drug interaction definitions .....	6
1.6 Classification of drug interactions .....	10
1.6.1 Pharmaceutical interactions .....	10
1.6.2 Pharmacokinetic interactions .....	11
1.6.3 Pharmacodynamic interactions .....	12
1.7 Cancer patients and drug-drug interactions .....	13
1.8 When interactions are most likely to occur .....	15
1.9 Problems of interaction research in cancer patients .....	16
1.10 Minimization of drug interactions .....	17
<b>Chapter 2: Study aim and objective</b> .....	18
<b>Chapter 3: Research methodology</b> .....	19
3.1 Study design .....	19
3.2 Methods .....	20

3.2.1 Data collection methods .....	20
3.2.2 Detection of potential DDIs .....	22
3.2.3 Outcome measures .....	22
3.2.4 Statistical methods .....	24
3.3 Educational materials .....	24
3.3.1 Wall chart.....	24
3.3.2 Brochure .....	28
3.3.3 Awareness step .....	35
<b>Chapter 4: Results .....</b>	<b>36</b>
4.1 Phase 1: pre-intervention assessment.....	36
4.2 Phase 3: post-intervention assessment.....	38
4.3 Comparison of pre-intervention and post-intervention phases.....	40
4.4 Details of potential drug-drug interactions detected .....	41
<b>Chapter 5: Discussion.....</b>	<b>81</b>
5.1 Scope and methodology of the study .....	81
5.2 Limitations of the study .....	88
<b>Chapter 6: Conclusion.....</b>	<b>89</b>
6.1 Conclusion .....	89
6.2 Recommendations.....	90
6.3 Recommendations for future research .....	91
<b>References.....</b>	<b>93</b>
<b>Summary.....</b>	<b>113</b>
<b>الملخص باللغة العربية</b>	

## ACKNOWLEDGEMENT

*Thanks God, the faithful and the merciful, by the grace and the blessings of whom, this work was possible, for providing me the opportunity to step in the amazing world of science, to be able to step strong and smooth in this way.*

*I'd like to express my deepest gratitude, great respect and profound thanks to **Prof. Dr. Osama Badary**, Professor and Head of Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, who taught me the alphabet of Clinical Pharmacy, and whose sincerity and encouragement I will never forget.*

*I'm particularly thankful and grateful to **Prof. Dr. Sohair Sayed Esmaeel**, Professor of Oncology, Faculty of Medicine, Ain Shams University, for her valuable encouragement during the practical part of study.*

*I'd like to acknowledge the advice and guidance of **Dr. Mahmoud Abbass El-Laithy**, Lecturer of Oncology, Faculty of Medicine, Ain Shams University, for his guidance, cooperation, and encouragement throughout the study.*

*I can't forget to thank my amazing teachers in Notre Dame des Apôtres School, because having a great teacher is life-changing.*

*Sincere thanks to all my family and friends who helped, supported and encouraged me.*

## **List of abbreviations**

5-FU	5-fluorouracil
ACE	Angiotensin converting enzyme
ADE	Adverse drug event
ADR	Adverse drug reactions
AUC	Area under the curve
DDI	Drug-drug interaction
DI	Drug interactions
INR	International normalized ratio
MTX	Methotrexate
NSAIDs	Non steroidal anti inflammatory drugs
PDDI	Potential drug-drug interactions
PDI	Potential drug interactions
TDM	Therapeutic drug monitoring
WHO	World Health Organization
SPSS	Statistical Package for Social Science
NCI	National Cancer Institute
MIMS	Master Index of Medical Specialties
ECG	Electrocardiograph

## **List of tables**

Table	Title	Page
1	Data collection methods used in the present study	21
2	Classification of drug-drug interactions according to level of scientific evidence	23
3	Classification of drug-drug interactions according to degree of severity	23
4	Details of figure(5) (wall chart)	26
5	Details of figure(6) (brochure)	29
6	PDDIs in phase (1) (pre-intervention phase) - anticancer/anticancer, anticancer/non-anticancer, non-anticancer/non-anticancer- classified according to their degrees of severity	37
7	PDDIs in phase (1) (pre-intervention phase) - anticancer/anticancer, anticancer/non-anticancer, non-anticancer/non-anticancer- classified according to their levels of scientific evidence:	37
8	PDDIs in phase (3) (post-intervention phase) - anticancer/anticancer, anticancer/non-anticancer, non-anticancer/non-anticancer- classified according to their degrees of severity:	39
9	PDDIs in phase (3) (post-intervention phase) - anticancer/anticancer, anticancer/non-anticancer, non-anticancer/non-anticancer- classified according to their levels of scientific evidence	39
10	Comparison of percent of interactions in the different degrees of severity of DDIs between pre-intervention and post-intervention phases.	41
11	PDDIs of fluorouracil	42
12	PDDIs of cyclophosphamide	44
13	PDDIs of anthracyclines	47
14	PDDIs of methotrexate	48
15	PDDIs of platinum compounds	50
16	PDDIs of vinca alkaloids	54
17	PDDIs of ifosfamide	55
18	PDDIs of irinotecan	56
19	PDDIs of taxanes	57
20	PDDIs of etoposide	58

21	PDDIs of bleomycin	59
22	PDDIs of cytarabine	60
23	PDDIs of NSAIDs	61
24	PDDIs of paracetamol	64
25	PDDIs of ACE inhibitors	65
26	PDDIs of carbamazepine	66
27	PDDIs of tramadol	69
28	PDDIs of ranitidine	70
29	PDDIs of metoclopramide	71
30	PDDIs of calcium	72
31	PDDIs of phenytoin	73
32	PDDIs of allopurinol	74
33	PDDIs of furosemide	75
34	PDDIs of omeprazole	76
35	PDDIs of quinolones	77
36	PDDIs of fluconazole	78
37	PDDIs of steroids	79
38	PDDIs of metformin	80

## **List of figures**

Figure	Title	page
1	The Swiss cheese model of adverse drug outcomes	7
2	The Swiss cheese model of adverse drug outcomes (defense sources)	8
3	The Swiss cheese model of adverse drug outcomes (holes line up)	9
4	Description of a prescription	20
5	Drug-drug interaction wall chart	25
6	Drug-drug interaction brochure	29
7	Classification of collected PDDIs in phase (1) (pre-intervention phase) into anticancer/anticancer, anticancer/non-anticancer, non-anticancer/non-anticancer	36
8	Classification of collected PDDIs in phase ( 3) (post-intervention phase) into anticancer/anticancer, anticancer/non-anticancer, non-anticancer/non-anticancer	38
9	Comparison of the average number of PDDIs in prescriptions in phase (1)(pre-intervention) and phase (3)(post-intervention)	40



## **Abstract**

### **Background and objectives:**

The pharmacological treatment of patients with cancer is associated with multiple side-effects. Although the cause of side-effects usually lies in the toxicity and narrow therapeutic index of the cytotoxic drugs themselves, drug-drug interactions (DDIs) can reinforce or intensify adverse events and even seem to be the cause of hospital admission and death in cancer patients. Polypharmacy is the main cause of DDIs. Cancer patients commonly receive multiple medications, including cytotoxic chemotherapy, hormonal agents and supportive care drugs. Most of cancer patients are elderly, and so require medications for co-morbid conditions such as cardiovascular, gastrointestinal, and hematologic diseases. The age-related decline in hepatic and renal function reduces their ability to metabolize and clear drugs and so increases the potential for toxicity. Most of the available literature about the incidence of DDIs and their prevention in cancer patients was performed in developed countries. There is no published information regarding the incidence and prevention of DDIs in Egypt or any other country in Middle East. This study aimed to explore the incidence of potential DDIs as well as their severity and degree of scientific evidence, and perform a care plan to minimize their incidence in oncology patients.

### **Methods:**

The current study was a pre-post study of the potential drug-drug interactions in the oncology department of Ain Shams University Hospital in Cairo, Egypt. The study involved a total of 1000 prescription in the oncology department (500 in the pre-intervention phase, 500 in the post-intervention phase). Potential DDIs were detected using the following drug information resources: Text books (Stockley's

Drug Interactions and Drug Interactions in the Therapy of Malignant Diseases), Published studies on Pubmed, and Internet drug interactions checking systems (“Drug” drug interaction checker, “Medscape” drug interaction checker and “MIMS” -master index of medical specialties- drug interaction checker). G-standard was used to classify the detected interactions according to their degree of severity and level of scientific evidence. The incidence, degree of severity and level of scientific evidence of the detected potential DDIs were determined in pre-intervention phase of the study. This was followed by implementing DDIs reducing measures to deliver the detected results to physicians in the form of group meetings, wall charts, and brochures containing the detected potential DDIs. Post-intervention, incidence, degree of severity and level of scientific evidence were determined using the same methods for DDIs detection and classification in the pre-intervention phase of the study.

## **Results:**

Pre-intervention phase: 500 prescription analyses resulted in 1440 potential drug-drug interaction, that the average interaction per prescription was 2.88 interactions per prescription. Interactions between two cytotoxic drugs (into anticancer/anticancer) were 313(21.8%), Interactions between a cytotoxic drug and a non-cytotoxic one (anticancer/non-anticancer) were 642(44.5%) and interactions between two non-cytotoxic drugs (non-anticancer/non-anticancer) were 485(33.7%). These interactions were classified by taking G-standard as a guide. According to degree of severity interactions were: grade A (4.5%), grade B (12.6%), grade C (9.5%), grade D (15.2%), grade E (55%) and grade F (3.2%).

Post-intervention phase: 500 prescriptions were analyzed after intervention phase and results were compared to those of pre-intervention phase. The total number of interactions was 1116 interaction (DDIs decreased by 22.5%). Interactions between two cytotoxic drugs (into anticancer/anticancer) were 204(18.3%),

Interactions between a cytotoxic drug and a non-cytotoxic one (anticancer/non-anticancer) were 556(49.8%) and interactions between two non-cytotoxic drugs (non-anticancer/non-anticancer) were 356(31.9%). According to degree of severity interactions were: grade A (6.1%), grade B (10.75%), grade C (5.74%), grade D (18.91%), grade E (53.4%) and grade F (5.1%). Using unpaired t-test, showed that there is no statistical difference between mean number of potential DDIs in pre-intervention and post-intervention phases ( $P = 0.447$ ). Using of Wilcoxon signed ranks test, showed that there is no statistical difference in percent of potential DDIs in the different degrees of severity between pre-intervention and post-intervention phase ( $Z=0$  ,  $P= 1$ ).

### **Conclusion:**

High incidence of potential DDIs was found in the current study. Clinical pharmacist's activities focusing on improving drug knowledge and awareness of DDIs were shown effective in reducing their incidence. These activities didn't remove all the risks and cancer patients at the hospital are still subjected to significant potential DDIs. This calls for more pharmacists' involvement in medication use process to improve patients' safety.

# **Introduction**

## **Chapter 1**

### **Introduction**

#### **1.1 components and scope of clinical pharmacy practice**

There are eight basic components of clinical pharmacy practice; Prescribing drugs, Administering drugs, Documenting professional services, Reviewing drug use, Communication, Counseling, Consulting and Preventing Medication Errors (**Betty, 2010**). While the scope of clinical pharmacy comprised of: Drug Information, Drug Utilization, Drug Evaluation and Selection, Medication Therapy Management, Formal Education and Training Program, Disease State Management and Application of Electronic Data Processing. The major segments of this discipline are pharmacovigilance, pharmacoconomics, therapeutic drug monitoring (TDM), biosafety, drug information, and aseptic dispensary.

The probability of wrong medication can be reduced if the prescription are reviewed properly, the clinical plan evaluates the situation correctly and pharmaceutical services are provided (**Teichman and Caffee, 2002**). World Health Organization (WHO) highlighted the importance of pharmacovigilance as a useful constraint to minimize the therapeutic complications by detection, assessment, understanding and prevention of adverse effects of medicine (**WHO,2002**).

#### **1.2 Role of clinical pharmacist in oncology unit** (**Hoare and Beer, 1995**):

##### **a) Multidisciplinary approach**

- Treatment of cancer patients is multidisciplinary. The oncology pharmacist should be aware of the role of doctors, nurses and other therapists in their unit and liaise closely with them on all drug-related aspects of patient care, to ensure continuity, consistency and safety in the use of drugs.

### **b) Communication**

- Formal lines of communication should be set up between the pharmacists at the cancer unit to ensure effective and efficient flow of information in both directions.

### **c) Therapeutic policies**

- The oncology pharmacist should ensure the approved therapeutic policies for areas of cancer care specific to oncology medicine are in operation. Written policies must be available in all oncology and pharmacy clinical areas and cancer units linking in to the cancer center.

### **d) Dispensing**

- It is recommended that at least one pharmacist, experienced in oncology pharmacy must be available for prescription checking and/or advice. Written procedures for the dispensing of oral cytotoxic drugs, including inpatient supply, must individually dispensed and labeled with full dosing instructions and the length of course.

### **e) Patient counseling**

- Patient counseling by pharmacist about the nature of their treatment is particularly important for the oncology patient, because they receive multiple drug therapy and have frequently changing dosage regimens and short courses of drugs superimposed on chronic treatments.

### **f) Cytotoxic reconstitution**

- Cytotoxic preparation must be managed by a pharmacist with permanent responsibility for the service and be staffed by technicians. Cytotoxic reconstitution should be in a pharmacy or pharmacy satellite. If –unavoidably– preparation occurs outside the pharmacy, pharmacists must be involved in the

preparation and maintenance of procedures and training of medical and/or nursing staff. Procedures must be available for handling techniques, dose preparation, dealing with spillage and disposal of cytotoxic drugs.

### **g) Drug information**

- Much of oncology practice is research based and therefore not in textbooks. The oncology pharmacist should provide their drug information service or have access to a drug information service.

### **h) Clinical trials**

- There should be a designated, named pharmacist responsible for liaising with the clinical research team and the sponsor on all pharmaceutical aspects of clinical trials. The pharmacist should be involved at all stages of the clinical trial to ensure the safety of patients and the provision of robust data to Food and Drug Administration or good clinical practice standards.

### **i) Oncology training**

The basic standard of training pharmacists and pharmacy technicians working in oncology should include clinical and technical training.

## **1.3 Review of the role of oncology clinical pharmacist in literature**

Drug –drug interactions (DDIs) are a cause of adverse drug reactions (ADRs), resulting in adverse outcomes associated with drug therapy (**Cruciol-Souza and Thomson, 2006**). In 2004, some researchers have authored a paper titled “*Death by Medicine*” that presents compelling evidence that today’s system frequently causes more harm than good (**Gary et al., 2004**). This paper has